Agile and Flexible Capital Policy and Enhanced IR Activities
First written in FY2017. 1 of 3 entries say "Restated". Latest entry: 2026-08-20.
90 other companies' latest entry also says "Advanced".
- 2026-08-20AdvancedEarnings presentation
「 Secure ¥1 billion of internal funds as working capital to cover approximately 1 year of required cash Secure ¥500 million for strategic investments, including M&A and capital investment Cash flow generated in excess of these amounts will be returned to shareholders through dividends and treasury share purchases」
The company specified the allocation of capital among working capital, strategic investment funds, and excess cash flow. - FY2019RestatedAnnual report
「We will pursue an agile and flexible capital policy, including the diversification of funding methods. In addition, dialogue with the market through information disclosure and other means is important to enhancing the corporate value of our Group, so we will also work to strengthen our IR activities.」
The company continues to pursue the diversification of funding methods and stronger IR activities. - FY2017First statedAnnual report
「We will pursue an agile and flexible capital policy, including the diversification of funding methods. In addition, dialogue with the market through information disclosure and other means is important to enhancing the corporate value of our Group, so we will also work to strengthen our IR activities.」
The company has set out the diversification of funding methods to secure investment funds for its biomarker business, together with enhanced IR activities aimed at dialogue with the market.